CBio featured on The Art of Manufacturing podcast

David Charlot and Kris Z
David Charlot and Kris Z

Los Angeles, CA - David Charlot, PhD, CEO of CBio, is the latest featured guest on The Art of Manufacturing podcast. The show, hosted by Krisztina ‘Z’ Holly, presents a behind-the-scenes look at entrepreneurs who are trying to "make it". The podcast is produced in collaboration with MAKE IT IN LA, a community of creators turning passions into products in Los Angeles.

David talks about CBio’s new way to understand the body and diagnose disease without killing the cells, as well as the state of the art in biology, and how CBio is scaling the business without outside investment.

The Art of Manufacturing is recorded in the great, modern LADWP’s La Kretz Innovation Campus, a fully renovated 60,000 square foot building located at 5th and Hewitt Streets in the dynamic Arts District of Downtown Los Angeles.

If you like podcasts, you should check out The Art of Manufacturing! Listen here.

#podcast #startuplife #cellPhoresis #biotech

About Dr. Charlot

David is an experienced inventor, entrepreneur, and manager with 15 years experience building tools to solve challenges in human health. He is a knowledgeable bioengineer with specialization in automation and systems integration for live cell analysis. He received his PhD in bioengineering from University of California, San Diego and BSc in physics from Delaware State University. David has 18 device patents for DNA and Cell Analysis issued in the US.

As CEO of CBio, David leads a multidisciplinary team to implement his vision to provide access to novel tools clinicians and researchers need to detect treatable disease early. His core passions are providing access to advanced live cell analysis tools and expanding opportunities in STEM education. He believes empowering the next generation of researchers with disruptive technology will spark their creativity and reshape the future of clinical diagnostics.

About CBio

CBio is a life science tools company equipping researchers and clinicians with tools to help them identify predictive signatures of disease. Our proprietary cellPhoresis™ platform enables the study of living cells. Our technology identifies subtle differences between Normal and Abnormal living cells, preserves function, and retains usability for further study.